CytoMed Therapeutics (GDTC) Operating Leases (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Operating Leases of $41249.3 for Q4 2025, down 30.4% sequentially from $59267.0 in Q2 2025, and up 138.27% YoY from $17311.9 in Q4 2024.
CytoMed Therapeutics (GDTC) Operating Leases (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Operating Leases for 5 years, with the latest figure at $41249.3 in Q4 2025.
- Quarterly Operating Leases rose 138.27% year-over-year to $41249.3 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $41249.3 (up 138.27% YoY) and the FY2025 annual result came in at $41575.0, up 141.17% from the prior year.
- Operating Leases fell to $41249.3 in Q4 2025 per GDTC's latest filing, from $59267.0 in the prior quarter.
- Over five years, Operating Leases peaked at $59267.0 in Q2 2025 and troughed at $112.0 in Q2 2024.
- A 5-year average of $17380.5 and a median of $8061.0 in 2021 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2024 and 2025: Operating Leases plunged 62.42% in 2024, then soared 52816.96% in 2025.
- Over 5 years, Operating Leases stood at $11287.7 in 2021, then tumbled by 57.17% to $4834.3 in 2022, then declined by 3.11% to $4684.1 in 2023, then surged by 269.59% to $17311.9 in 2024, then surged by 138.27% to $41249.3 in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $41249.3, $59267.0, and $17311.9 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41,249.33 |
| Jun 30, 2025 | 59,267.00 |
| Dec 31, 2024 | 17,311.91 |
| Jun 30, 2024 | 112.00 |
| Dec 31, 2023 | 4,684.14 |
| Jun 30, 2023 | 298.00 |
| Dec 31, 2022 | 4,834.25 |
| Dec 31, 2021 | 11,287.67 |